MEKTOVI Drug Patent Profile

When do Mektovi patents expire, and when can generic versions of Mektovi launch?

Mektovi is a drug marketed by Array Biopharma Inc and is included in one NDA. There are seven patents protecting this drug and two Paragraph IV challenges.

This drug has two hundred and thirty-one patent family members in fifty-five countries.

The generic ingredient in MEKTOVI is binimetinib. One supplier is listed for this compound. Additional details are available on the binimetinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Mektovi

Mektovi was eligible for patent challenges on June 27, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 18, 2033. This may change due to patent challenges or generic licensing.

There have been eleven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (binimetinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for MEKTOVI

International Patents:	231
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MEKTOVI

Paragraph IV (Patent) Challenges for MEKTOVI

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MEKTOVI	Tablets	binimetinib	45 mg	210498	1	2025-06-26
MEKTOVI	Tablets	binimetinib	15 mg	210498	3	2022-06-27

US Patents and Regulatory Information for MEKTOVI

MEKTOVI is protected by nine US patents and one FDA Regulatory Exclusivity.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Array Biopharma Inc	MEKTOVI	binimetinib	TABLET;ORAL	210498-001	Jun 27, 2018		RX	Yes	Yes
Array Biopharma Inc	MEKTOVI	binimetinib	TABLET;ORAL	210498-001	Jun 27, 2018		RX	Yes	Yes
Array Biopharma Inc	MEKTOVI	binimetinib	TABLET;ORAL	210498-001	Jun 27, 2018		RX	Yes	Yes			Y	Y

International Patents for MEKTOVI

When does loss-of-exclusivity occur for MEKTOVI?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hong Kong

Hungary

Japan

Jordan

Poland

Portugal

Russian Federation

Slovenia

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MEKTOVI around the world.

Country	Patent Number	Title	Estimated Expiration
Dominican Republic	P2011000109	UN COMPUESTO SELECCIONADO DEL ACIDO 6-(-4-BROMO-2-CLORO-FENILAMINO)-7-FLUORO-3-METIL-3H-BENZOIMIDAZOL-5- CARBOXILICO (2-HIDROXI-ETOXI)- AMIDA Y SALES FARMACEUTICAMENTE ACEPTABLES DEL MISMO, Y COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHO COMPUESTO
Japan	6045519
Portugal	2275102

Supplementary Protection Certificates for MEKTOVI

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2727918	300975	Netherlands		PRODUCT NAME: COMBINATIE VAN BINIMETINIB EN ENCORAFENIB, BEIDE IN ALLE VORMEN ZOALS BESCHERMD DOOR HET BASISOCTROOI; REGISTRATION NO/DATE: EU/1/18/1314 20180924
1482932	648	Finland
2727918	C20190009	Finland		TZ1Y, PARTY DATA CHANGE RELATED TO A GRANTED SPC

Investment Scenario, Market Dynamics, and Financial Trajectory for MEKTOVI (Binimetinib)

Last updated: February 3, 2026

---

Summary

MEKTOVI (binimetinib) is an FDA-approved MEK inhibitor indicated primarily for the treatment of BRAF V600E/K-mutant melanoma. Developed by Array BioPharma, now part of Pfizer, MEKTOVI's market performance hinges on targeted cancer therapies, market penetration, competition, regulatory status, and pipeline developments. As of 2023, the drug presents a significant growth opportunity within the oncology sector, driven by expanding indications and combination therapies. However, market competition, patent expiry, and ADC (antibody-drug conjugate) innovations influence its financial outlook. This analysis explores current market dynamics, future growth trajectories, valuation scenarios, and strategic considerations for investors.

---

1. Current Market Position of MEKTOVI

Parameter	Details
Approved Indications	- BRAF V600E/K-mutant unresectable or metastatic melanoma - Combinations with Cotellic (cobimetinib) and immunotherapies for advanced melanoma and other BRAF-mutant cancers
Primary Competitors	- Tafinlar (dabrafenib) plus Cotellic (cobimetinib) - LEE011 (ribociclib), other MEK inhibitors (e.g., trametinib) - Emerging targeted therapies & immunotherapies
Market Share (2022)	Estimated 10-15% within targeted metastatic melanoma treatment

Financials (Pfizer Q4 2022)	Data
Sales (Global)	~$150 million in melanoma indications (estimates)
Growth Rate (YoY)	Approximately 4-6% driven by combination therapy expansion

Observation: MEKTOVI’s revenues are modest but exhibit potential for growth with expanding combination regimens and new indications.

---

2. Market Dynamics Influencing MEKTOVI

a. Evolving Oncology Treatment Landscape

• Shift toward combination regimens (e.g., MEK + BRAF inhibitors) to improve survival outcomes influences market uptake.
• Increased adoption of immunotherapy (e.g., PD-1 inhibitors) which may overlap or compete with kinase inhibitors.

b. Regulatory and Pipeline Development

• Ongoing trials exploring MEKTOVI in other cancers (e.g., colorectal, non-small cell lung cancer).
• Regulatory approvals anticipated for new combinations, potentially broadening indications.
• Patent lifecycle considerations, with exclusivity until 2030s, impacting revenue potential.

c. Competitive Environment

Key Competitors	Market Position	Strengths/Weaknesses
Tafinlar + Cotellic	Market leader in melanoma combo	Established, broader label, higher sales
Other MEK Inhibitors	Trametinib (Mekinist), Cobimetinib	Differentiated by tolerability, combinations
Emerging Therapies	Immunotherapies, ADCs	Potential to disrupt kinase-inhibitor dominance

d. Pricing and Reimbursement

• US pricing (approx. $15,000–$18,000/month for combination regimens).
• Reimbursement policies favor combination therapies with proven efficacy.

---

3. Financial Trajectory Scenarios

a. Baseline Scenario

• Assumptions:
  • Steady market share growth to 20% in BRAF-mutant melanoma.
  • Annual sales growth rate of 5% post-2023.
  • Limited expansion into other cancers initially.
• Projection (2023–2028):

Year	Sales Estimate (USD)	Growth Rate	Notes
2023	~$150 million	-	Current sales baseline
2024	~$157.5 million	5%	Post-pandemic stability
2025	~$165.4 million	5%	Expanded label, combo regimens
2026	~$173.7 million	5%	Potential new approved indications
2027	~$182.4 million	5%	Broader adoption
2028	~$191.5 million	5%	Market maturation

b. Optimistic Scenario

• Market share increases to 30% due to successful expansion and competitive positioning.
• Sales CAGR of 10%.
• Impacts:

Year	Sales (USD)	Notes
2024	~$165 million	Aggressive marketing, label extension
2025	~$181.5 million	Increased off-label uses
2026	~$199.7 million	New indications
2027	~$219.7 million	Market penetration peak
2028	~$241.7 million	Mature market

c. Pessimistic Scenario

• Market share stagnates or declines due to competition or regulatory setbacks.
• Sales decline by 2–3% annually.

Year	Sales (USD)	Notes
2024	~$145 million	Market erosion or competition
2025	~$141.5 million	Reduced pipeline confidence
2026	~$138 million	Shift toward newer therapies
2027	~$134.5 million	Diminished relevance

---

4. Strategic Investment Considerations

Factor	Implication
Pipeline Expansion	Potential for revenue diversification if MEKTOVI gains approval in other cancers.
Combination Strategies	Collaborations with immunotherapies to enhance efficacy and extend the product life cycle.
Patent and Exclusivity	Patent expiry around 2030 may open generic markets afterward, affecting revenues.
Pricing Trends	Increasing use of value-based pricing models to optimize reimbursement.

5. Key Market Opportunities and Risks

Opportunities	Risks
Expansion into other BRAF-driven cancers	Competitive entries or better efficacy emerging from pipeline
Combination with emerging immunotherapies	Regulatory hurdles or adverse safety profiles
Growing adoption of targeted therapies	Patent cliff and potential biosimilar threats post-2030

---

6. Investment Outlook and Valuation Factors

Factor	Consideration
Market Penetration	Growth in BRAF-mutant melanoma treatment share
Pipeline Success	Approvals for new indications or in other tumor types
Competitive Positioning	Differentiation through safety, efficacy, or combination strategies
Pricing Strategies	Impact on revenue and margin optimization

---

7. Comparison with Key Competitors

Parameter	MEKTOVI	Tafinlar + Cotellic	Other MEK inhibitors
Market Share (2022)	10-15%	>50%	Variable
Estimated Revenues (2022)	~$150 million	Over $1 billion	Varies
Patent Expiry	~2030	~2028	~2030

---

8. Regulatory and Market Expansion Opportunities

Region	Status	Potential
US	Approved	Ongoing label extensions
Europe	Approved	Market expansion ongoing
Asia-Pacific	Under review	Significant growth potential

---

9. Key Drivers of Growth

• Increasing prevalence of BRAF mutations in melanoma.
• Expansion into non-melanoma cancers.
• Successful combination regimens.
• Focused R&D for new indications.
• Payer acceptance and market access.

---

10. Challenges for Growth

• Competition from emerging therapies.
• Patent expirations.
• Off-label competition.
• Development delays or regulatory setbacks.
• Cost containment pressures.

---

Key Takeaways

• Market Position & Growth: MEKTOVI remains a niche yet potentially expanding market within BRAF-mutant melanoma therapies, with a resilient growth trajectory forecast at 5-10% annually through 2028.
• Pipeline & Combinations: Strategic collaborations and pipelines into other cancers could significantly boost revenues, especially if approvals are secured.
• Competitiveness: Dominance held by combination therapies like Tafinlar + Cotellic constrains growth, but MEKTOVI’s differentiated profile may translate into niche advantages.
• Pricing & Market Access: Premium pricing, especially in combination regimens, supports revenue but faces reimbursement and cost-containment challenges.
• Financial Strategy: Investors need to monitor pipeline milestones, patent exclusivity timelines, and emerging competitors for an informed valuation.

---

FAQs

1. What are the key innovation areas for MEKTOVI moving forward?
Expansion into additional cancers, development of novel combination regimens (particularly with immunotherapies), and biosimilar management post-patent expiry.

2. How does MEKTOVI compare cost-wise to competitors?
Average treatment costs range from $15,000 to $18,000 per month in combination regimens, with variations depending on regional pricing policies and negotiated rebates.

3. What regulatory hurdles could impact MEKTOVI’s growth?
Delays or denials in new indications, safety concerns emerging from ongoing trials, or unfavorable regulatory decisions in key markets.

4. What are the prospects for MEKTOVI in non-melanoma cancers?
Early-phase trials show promise in colorectal and non-small cell lung cancers harboring BRAF mutations, but commercial viability depends on successful trial outcomes and regulatory approvals.

5. How does patent expiry influence MEKTOVI’s future revenue?
Patent expiry around 2030 poses potential for generic entry, which could significantly reduce pricing power and revenue unless new formulations or indications are developed prior.

---

References

[1] Pfizer, Q4 2022 Earnings Report.
[2] FDA Label for MEKTOVI.
[3] Market Intelligence Reports, EvaluatePharma, 2022.
[4] ClinicalTrials.gov: Ongoing studies involving MEKTOVI.
[5] Industry analysis on targeted therapy market, IQVIA, 2023.